Kliniken & Institute … Kliniken Zentrum für Kinder- und… Welcome Research Scientific…

Wissenschaftliche Kooperationen

Molecular Medicine Partnership Unit (MMPU)

Founded in 2002, the Molecular Medicine Partnership Unit (MMPU) is a joint venture of Heidelberg University Hospital and the EMBL. Eight international working groups consisting of medical and basic researchers address the molecular processes underlying common diseases, their pathogenesis, diagnosis and therapy. The MMPU is headed by Prof. Dr. Andreas Kulozik and Prof. Dr. Matthias Hentze. The website of the MMPU can be accessed here Opens external link in new windowMMPU UniveritätsKlinikum, and here Opens external link in new windowMMPU EMBL.

 

Staff members of the Department of Pediatric Oncology, Hematology, Immunology and Pulmonology are involved in four MMPU groups:

Opens external link in new windowBlood Diseases

Opens external link in new windowIron Homeostasis

Molecular Pediatric Oncology

 

 


Clinical Cooperation Unit Pediatric Oncology

The Opens external link in new windowClinical Cooperation Unit (CCU) Pediatric Oncology is a department of the DKFZ that has strong structural ties to the Department of Pediatric Oncology, Hematology, Immunology and Pulmonology. The CCU has been headed by Prof. Dr. Olaf Witt since 2008. The department aims at developing new and experimental methods of treating tumors of the nervous system in children and adolescents and testing these methods in clinical trials.

 


Division of Pediatric Neurooncology

Headed by Prof. Dr. Stefan Pfister, the Opens external link in new windowDivision of Pediatric Neurooncology at the DKFZ is the result of a long and intensive cooperation between the Department of Pediatric Oncology, Hematology, Immunology and Pulmonology (Prof. Dr. Andreas Kulozik), the Clinical Cooperation Unit Pediatric Oncology (Prof. Dr. Olaf Witt) and the Division of Molecular Genetics at the DKFZ (Prof. Dr. Peter Lichter). The research group has set itself the task of translating genetic and epigenetic information into clinical applications, whether as biomarkers or as new treatment options for children with brain tumors.

 


 

CRC 1036

The Collaborative Research Center Opens external link in new windowCRC 1036 is a joint project of the Faculty of Biosciences and Heidelberg University Hospital, the DKFZ and the EMBL that has been funded by the German Research Foundation (DFG) since 2012. The project aims at establishing a new focus of research at these institutions: Cellular Surveillance and Damage Response. The speaker of this CRC is ZMBH director Prof. Dr. Bernd Bukau, vice speakers are Prof. Dr. Andreas Kulozik and Prof. Dr. Frauke Melchior.

 

 


DFG FOR 855

The Opens external link in new windowDFG Research Group 855, is a collaborative project of various national research groups in the area of "cytoplasmic regulation of gene expression" that has been supported by DFG funding since 2007; the speaker of the project is Opens external link in new windowProf. Dr. Elmar Wahle, Halle.

 


EU network

The working group of Prof. Martina Muckenthaler is involved in a BMBF-funded joint research project. Supported by partners in France, Italy and Spain, this group improves the diagnosis of rare congenital anemias and develops new treatment strategies.  Opens external link in new windowERA-NET.

 


Center for Rare Diseases

The Center for Rare Blood Disorders headed by Prof. Muckenthaler and Prof. Andreas Kulozik is part of the Center for Rare Diseases of Heidelberg University Hospital. The purpose of the Center for Rare Blood Disorders is to diagnose and treat congenital blood disorders. These conditions include a wide range of very rare disorders that impair the functioning or formation of hemoglobin, of the coagulation factors in the plasma or of the blood cells themselves. Professor Muckenthaler also serves on the board of directors of the Center for Rare Diseases. Opens external link in new windowBMBF:HMA-Iron.
The aim of the Cystic Fibrosis Center headed by Prof. Mall is to continue improving the patients' life expectancy and quality of life through early diagnosis and modern, individualized therapy.